Missed NVDA?
Don’t Miss the Next One.
Join 5,000+ investors using Ticker Nerd’s Market Radar to stay ahead of major market moves, analyst upgrades, and trending opportunities — for free.
MLAB Stock Forecast 2025-2026
$77.63
Current Price
$428.70M
Market Cap
Buy 1
Hold 2
Sell 0
Wall St Analyst Ratings
Distance to MLAB Price Targets
+48.1%
To High Target of $115.00
+22.4%
To Median Target of $95.00
-3.4%
To Low Target of $75.00
MLAB Price Momentum
-1.3%
1 Week Change
+2.1%
1 Month Change
-37.4%
1 Year Change
-41.1%
Year-to-Date Change
-50.0%
From 52W High of $155.12
+40.0%
From 52W Low of $55.45
📊 TOP ANALYST CALLS
Did MLAB Make This Month's Elite Buy List?
We don't follow just any analyst — only the top 3% with a proven track record make our cut. See if Mesa Labs is one of their latest high-conviction picks.
Latest MLAB Stock Price Targets & Analyst Predictions
Based on our analysis of 3 Wall Street analysts, MLAB has a neutral consensus with a median price target of $95.00 (ranging from $75.00 to $115.00). The overall analyst rating is N/A (N/A/10). Currently trading at $77.63, the median forecast implies a 22.4% upside. This outlook is supported by 1 Buy, 2 Hold, and 0 Sell ratings.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
MLAB Analyst Ratings
1
Buy
2
Hold
0
Sell
MLAB Price Target Range
Low
$75.00
Average
$95.00
High
$115.00
Current: $77.63
Latest MLAB Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for MLAB.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| Aug 8, 2025 | Wells Fargo | Brandon Couillard | Equal-Weight | Upgrade | $67.00 |
| May 30, 2025 | Wells Fargo | Brandon Couillard | Underweight | Maintains | $100.00 |
| Oct 1, 2024 | Evercore ISI Group | Vijay Kumar | Outperform | Maintains | $160.00 |
| Aug 27, 2024 | Wells Fargo | Brandon Couillard | Underweight | Initiates | $120.00 |
| Aug 6, 2024 | Evercore ISI Group | Vijay Kumar | Outperform | Maintains | $120.00 |
| Jul 2, 2024 | Evercore ISI Group | Vijay Kumar | Outperform | Maintains | $106.00 |
| Apr 4, 2024 | Evercore ISI Group | Vijay Kumar | Outperform | Maintains | $130.00 |
| Jan 4, 2024 | Evercore ISI Group | Vijay Kumar | Outperform | Upgrade | $125.00 |
| Jan 4, 2021 | Evercore ISI Group | Vijay Kumar | In-Line | Downgrade | $300.00 |
| Nov 10, 2020 | Keybanc | Sector Weight | Initiates | $N/A | |
| Nov 10, 2020 | KeyBanc | Sector Weight | Initiates | $N/A | |
| Oct 2, 2020 | JP Morgan | Neutral | Initiates | $N/A | |
| Dec 4, 2019 | Jefferies | Buy | Initiates | $N/A | |
| Aug 26, 2019 | Evercore ISI Group | Outperform | Initiates | $N/A | |
| Jun 10, 2016 | Sidoti & Co. | Neutral | Downgrade | $N/A | |
| Feb 10, 2016 | Janney Capital | Buy | Initiates | $N/A | |
| Feb 10, 2016 | Janney Montgomery Scott | Buy | Initiates | $N/A |
Mesa Laboratories Inc. (MLAB) Competitors
The following stocks are similar to Mesa Labs based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
Mesa Laboratories Inc. (MLAB) Financial Data
Mesa Laboratories Inc. has a market capitalization of $428.70M with a P/E ratio of 546.6x. The company generates $245.26M in trailing twelve-month revenue with a -0.6% profit margin.
Revenue growth is +5.0% quarter-over-quarter, while maintaining an operating margin of +7.8% and return on equity of -0.9%.
Valuation Metrics
Market Cap
$428.70M
Enterprise Value
$585.41M
P/E Ratio
546.6x
PEG Ratio
-19.1x
Price/Sales
1.7x
Growth & Margins
Revenue Growth (YoY)
+5.0%
Gross Margin
+61.5%
Operating Margin
+7.8%
Net Margin
-0.6%
EPS Growth
-27.8%
Financial Health
Cash/Price Ratio
+5.1%
Current Ratio
2.0x
Debt/Equity
100.1x
ROE
-0.9%
ROA
+2.1%
💡 SKIP THE NOISE
97% of Analyst Ratings Go Nowhere
We filter thousands of calls to find the few that actually matter. Get the top analyst buy ratings — tracked and updated every Monday and Thursday.
Mesa Laboratories Inc. (MLAB) Business Model
About Mesa Laboratories Inc.
What They Do
Manufactures critical equipment for regulated industries.
Business Model
The company develops and produces precision instruments and consumables for sectors like healthcare, pharmaceuticals, and food and beverage. It generates revenue by providing advanced monitoring systems, calibration devices, and sterilization products that adhere to strict regulatory standards, ensuring compliance and safety in critical processes.
Additional Information
Founded in 1982 and headquartered in Lakewood, Colorado, Mesa Laboratories is known for its innovation and reliability. The company continues to expand its product offerings through strategic acquisitions and ongoing research and development efforts.
Company Information
Sector
Technology
Industry
Scientific & Technical Instruments
Employees
730
CEO
Mr. Gary M. Owens
Country
United States
IPO Year
1995
Website
www.mesalabs.comMesa Laboratories Inc. (MLAB) Latest News & Analysis
Latest News
Quick Summary
Mesa Laboratories, Inc. (NASDAQ:MLAB) executives Gary Owens and John Sakys will attend upcoming conferences, as announced on November 12, 2025.
Why It Matters
CEO and CFO attendance at conferences signals potential strategic updates or insights, possibly impacting investor sentiment and stock performance for Mesa Laboratories.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
Mesa Laboratories, Inc. (NASDAQ:MLAB) will release its Q2 fiscal 2026 financial results on November 6, 2025, after market close.
Why It Matters
Mesa Laboratories' upcoming Q2 financial results could impact stock performance, influencing investor sentiment and expectations for future growth.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
Mesa Labs (MLAB) experienced significant trading volume recently, but current earnings estimate revisions may hinder its short-term upward momentum.
Why It Matters
Higher trading volume indicates increased interest and potential volatility in Mesa Labs (MLAB). Negative earnings estimate revisions could signal future weakness, impacting stock performance.
Source: Zacks Investment Research
Market Sentiment:
Positive
Quick Summary
Mesa Laboratories, Inc. repaid $97.5 million of its 1.375% Convertible Senior Notes due August 2025, drawing $97 million from its credit agreement to finance the repayment.
Why It Matters
Mesa Laboratories' repayment of $97.5 million in convertible notes indicates improved liquidity and financial stability, potentially enhancing investor confidence and affecting stock performance.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Mesa Labs Announces First Quarter Results
4 months ago
Quick Summary
Mesa Laboratories, Inc. (NASDAQ: MLAB) reported its 1Q26 results for the period ending June 30, 2025. Further financial details were shared in the announcement.
Why It Matters
Mesa Laboratories' Q1 2026 results may indicate financial health and growth potential, impacting stock performance and investor confidence.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
Mesa Labs (MLAB) reported quarterly earnings of $2.32 per share, below the Zacks Consensus Estimate of $2.46, and down from $2.83 per share from the previous year.
Why It Matters
Mesa Labs' earnings miss and year-over-year decline signal potential operational issues, which may lead to decreased investor confidence and impact stock performance.
Source: Zacks Investment Research
Market Sentiment:
Negative
Frequently Asked Questions About MLAB Stock
What is Mesa Laboratories Inc.'s (MLAB) stock forecast for 2026?
Based on our analysis of 3 Wall Street analysts, Mesa Laboratories Inc. (MLAB) has a median price target of $95.00. The highest price target is $115.00 and the lowest is $75.00.
Is MLAB stock a good investment in 2026?
According to current analyst ratings, MLAB has 1 Buy ratings, 2 Hold ratings, and 0 Sell ratings. The stock is currently trading at $77.63. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for MLAB stock?
Wall Street analysts predict MLAB stock could reach $95.00 in the next 12 months. This represents a 22.4% increase from the current price of $77.63. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is Mesa Laboratories Inc.'s business model?
The company develops and produces precision instruments and consumables for sectors like healthcare, pharmaceuticals, and food and beverage. It generates revenue by providing advanced monitoring systems, calibration devices, and sterilization products that adhere to strict regulatory standards, ensuring compliance and safety in critical processes.
What is the highest forecasted price for MLAB Mesa Laboratories Inc.?
The highest price target for MLAB is $115.00 from at , which represents a 48.1% increase from the current price of $77.63.
What is the lowest forecasted price for MLAB Mesa Laboratories Inc.?
The lowest price target for MLAB is $75.00 from at , which represents a -3.4% decrease from the current price of $77.63.
What is the overall MLAB consensus from analysts for Mesa Laboratories Inc.?
The overall analyst consensus for MLAB is neutral. Out of 3 Wall Street analysts, 1 rate it as Buy, 2 as Hold, and 0 as Sell, with a median price target of $95.00.
How accurate are MLAB stock price projections?
Stock price projections, including those for Mesa Laboratories Inc., are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
Last updated: December 8, 2025 2:48 PM UTC